Replies to post #127514 on Biotech Values

[read_this_n0w]

might it not be related to slower uptake? see it as a potential takeover candidate

[jbog]

This looks very similar to what I'm hearing regarding Novartis's poor Gilenya uptake. Insurance is the roadblock.

[DewDiligence]

DNDN made a new 2½ year low today (eom).